We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Informatics

Stay up to date on the topics that matter to you

CellProthera

CellProthera is a regenerative cell therapy developer specializing in cardiovascular diseases with a leading program in myocardial infarction. CellProthera has developed a unique GMP-compliant cell expansion process as well as a proprietary automation technology for in vitro production of large quantity of purified, CD34+ stem cells.

Latest CellProthera Content

Product News

CellProthera Begins Long-Term Observational Study To Demonstrate Safety and Efficacy of ProtheraCytes® Cell Therapy in Acute Myocardial Infarction

The long-term PERFECT observational study follows patients from successful Phase I/IIb of ProtheraCytes for the repair and regeneration of damaged cardiac tissues after severe heart attack.

Never miss a story

with the Breaking Science News daily newsletter